Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
135th Canton Fair Showcases Revolutionary Home Furnishing Innovations
ShenZhen ZhongShen AI DI Bedding Technology, stands at the forefront of bedding innovation driven by research and development, producing over 3000 new mattress designs annually including eco-friendly glue-free mattresses, AI smart mattresses, and natural wool mattresses. Their presented technology includes AI intelligent mattress series, leverages AI technology to instantly adapt to users' body characteristics providing an optimized sleep experience through vibration waves combined with sound…
PR Newswire
24/04/2024
SciBase Partners with Al Shirawi Healthcare solutions to Offer Nevisense in UAE
"We see the UAE as an attractive market with a passion for state-of-the-art, groundbreaking technologies. Partnering up with a well-resourced and knowledgeable ally will enable quick market access at a low investment cost. We see this as a way to increase our reach and help more people receive the best care possible," says Pia Renaudin, CEO at SciBase "We see the UAE as an attractive market with a passion for state-of-the-art, groundbreaking technologies. Partnering up with a…
PR Newswire
24/04/2024
Groupe Casino: The New Casino embarks on its transformation plan
The New Casino embarks on its transformation plan An organisation aligned with Casino Group's new scope 1Pooling of support services between brandsRe-internalisation of skillsPlan to strengthen purchasing partnerships with Intermarché and extend such partnerships to AuchanAn employment protection plan that is balanced among the various sites More than 1,000 jobs retained at the Saint-Étienne head officeBetween 1,293 and 3,267 job losses expected A proposed...
Nasdaq GlobeNewswire
24/04/2024
Pharming Group to report first quarter 2024 financial results on May 8
Leiden, the Netherlands, April 24, 2024:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 2024. Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on May 8, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information...
Nasdaq GlobeNewswire
24/04/2024
Vistin Pharma ASA: First quarter 2024 financial results
thof April 2024Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2024.Revenue in the first quarter ended at MNOK 104 compared to MNOK 101 in Q1 2023. Sales volume in the quarter was up by 11% compared to Q1 2023.First quarter EBITDA ended at MNOK 20 compared to MNOK 14 in Q1 2023, representing a 45% increase. EBITDA positively affected by increased sales volume and product mix, partly offset by a one-time inventory adjustment of MNOK 7.The net...
Nasdaq GlobeNewswire
24/04/2024
Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on…
Press ReleaseNicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of anad hocagentApril 24, 2024 – release at 07:30 CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary and Extraordinary General Meeting, having been unable to deliberate on April 10, 2024 as the quorum required by law has not been...
Nasdaq GlobeNewswire
24/04/2024
Ipsen delivers strong sales in the first quarter of 2024, driven by growth…
PARIS, FRANCE, 24 April 2024- Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. Q1 2024 Q1 2023 % change €m €m ActualCER 1Growth platforms 2 509.7452.012.8%16.2%New medicines 3 45.514.3n/an/aSomatuline ® 257.8263.2-2.0%-1.3%Other9.512.4-23.8%-20.5% Total Sales822.4741.910.9%13...
Nasdaq GlobeNewswire
24/04/2024
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in…
Group salesgrew by 2% 1at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appratioss fn of the Swiranc against most currencies,saleswere 6% lower when reported in CHF Pharmaceuticals Divisionbase business 2 grew by 7%, driven by strong sales of medicines to treat...
Nasdaq GlobeNewswire
24/04/2024
BioSenic postpones its annual general meeting of the shareholders and provides…
PRESS RELEASE - PRIVILEGED INFORMATIONIn view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of shareholders, so that the Enterprise Court of Nivelles can make a decision before the completion of the annual formalities. The Company believes that this postponement is preferable to ensure that the financial statements can be prepared on a going concern basis....
Nasdaq GlobeNewswire
24/04/2024
Pharming to be honored as Industry Innovator at National Organization for Rare…
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterizedLeiden, the Netherlands, April 24, 2024:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD®) at the Rare Impact Awards on June 8, 2024. The Rare...
Nasdaq GlobeNewswire
24/04/2024
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides…
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date are consistent with previously announced topline data observing no statistically significant or clinically meaningful effect of varoglutamstat on cognition and function in early AD up to 600mg twice a day (BID) doseStatistically significant...
Nasdaq GlobeNewswire
24/04/2024
Novartis and Medicines for Malaria Venture announce positive efficacy and safety…
There is currently no evidence-based treatment for the smallest babies with malariaThe CALINA study tested a new ratio and dose of Coartem ®(artemether- lumefantrine) to account for metabolic differences in babies under 5 kgThe CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review Basel, April 24, 2024– Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase...
Nasdaq GlobeNewswire
24/04/2024
Glycated Albumin Assay Market Projected to Reach $360.92 million by 2030 -…
The glycated albumin assay, an innovative diagnostic tool, is gaining importance worldwide for its ability to accurately measure glycated albumin levels in the blood, providing an essential alternative for diabetes management, especially for individuals facing inaccuracies with traditional HbA1c tests due to conditions such as hemoglobinopathies, recent blood transfusions, or chronic kidney or liver diseases. This test is essential in modifying diabetes treatment plans swiftly, aiming for…
PR Newswire
24/04/2024
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of…
BOSTON and LONDON, April23, 2024(GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected...
Nasdaq GlobeNewswire
24/04/2024
Global Corneal Implant Market is Expected to Showcase a Significant Growth at a…
Key Takeaways from the Corneal Implant Market Report Key Takeaways from the Corneal Implant Market Report To read more about the latest highlights related to the corneal implant market, get a snapshot of the key highlights entailed in theGlobal Corneal Implant Market Report Corneal Implant Overview Corneal implants, also known as corneal inlays, are innovative devices designed to correct refractive errors such as presbyopia, a condition where the eye's ability to focus on...
PR Newswire
23/04/2024
Endo, Inc. Completes Acquisition of Endo International plc's Assets
Following today's closing, Endo is poised for sustained growth and is strategically positioned to operate with a strong balance sheet, a broad, diversified portfolio of on-market medicines across its four segments, a deep pipeline of innovative and differentiated product candidates, and a highly skilled team. Following today's closing, Endo is poised for sustained growth and is strategically positioned to operate with a strong balance sheet, a broad, diversified portfolio of on-market…
PR Newswire
23/04/2024
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of…
BOSTON and LONDON, April23, 2024(GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a...
Nasdaq GlobeNewswire
23/04/2024
Novartis radioligand therapy Lutathera® FDA approved as first medicine…
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of diseaseNovartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate,...
Nasdaq GlobeNewswire
23/04/2024
Cobalt Sulphate Market Size to Grow USD 1.9 Billion by 2030 at a CAGR of 6.4% |…
Get Free Sample: https://reports.valuates.com/request/sample/ALLI-Auto-2S131/Cobalt_Sulphate_Market Get Free Sample: https://reports.valuates.com/request/sample/ALLI-Auto-2S131/Cobalt_Sulphate_Market Major Factors Driving the Growth of Cobalt Sulphate Market: The market for cobalt sulphate is expanding significantly because of its wide range of applications in different industries. Cobalt sulphate's qualities are highly prized because of its vital role in the creation of batteries...
PR Newswire
23/04/2024
Risklick: Protocol AI accelerates clinical trial development and patient access…
Developing new therapies typically requires an average of ten years and costs up to two billion dollars for companies. The most time-consuming and costly aspect of this process is the clinical trials, which are mandatory for validating new treatments before commercialization. These trials are complex, often resulting in significant delays or failures that impact both the cost and availability of new treatments for patients. Developing new therapies typically requires an average of ten years…
PR Newswire
23/04/2024
Invitation to Immunovia's Q1 presentation
Telephone numbers and webcastCall any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts. Telephone numbers and webcastCall any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts. Sweden : +46 (0)8 5051 0031United Kingdom : +44 (0) 207 107 06 13United States : +1 (1) 631 570 56 13 Link to the webcast: ...
PR Newswire
23/04/2024
Laboratory Filtration Market Worth $6.1 billion | MarketsandMarkets™
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12936082 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12936082 Browse in-depth TOC on "Laboratory Filtration Market" 740 - Tables56 - Figures559 - Pages Laboratory Filtration Market Scope: The membrane filters segment accounted for the largest share of the filters & filter media segment in the laboratory filtration market...
PR Newswire
23/04/2024
SciBase will present at the Redeye Medtech Event on April 24th
For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail:
[email protected]
For additional information, please contact: Pia Renaudin, VD, tel. +46732069802, e-mail:
[email protected]
Certified Advisor (CA):Vator Securities Tel: +46 8 580 065 99 Email:
[email protected]
About SciBase: SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and...
PR Newswire
23/04/2024
Navamedic ASA: Invitation to 2024 1st quarter presentation
Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail:
[email protected]
Hjarrand, CFO, +47 917 62 842 E-mail:
[email protected]
Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail:
[email protected]
Hjarrand, CFO, +47 917 62 842 E-mail:
[email protected]
About Navamedic Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and...
PR Newswire
23/04/2024
Altri Comunicati